{
 "company": "science-37",
 "as_of": "2026-10-09",
 "choices": [
  {
   "id": "science-37-p01",
   "business": "Decentralized clinical-trial technology and delivery",
   "category": "product",
   "dimension": "Platform and services",
   "statement": "Science 37 sold platform access and trial delivery services.",
   "event_date": "2021-12-31",
   "date_precision": "day",
   "evidence_kind": "documented_offer_or_action",
   "sources": [
    "SC1"
   ]
  },
  {
   "id": "science-37-p02",
   "business": "Decentralized clinical-trial technology and delivery",
   "category": "product",
   "dimension": "Delivery network",
   "statement": "Mobile clinicians and investigators supported decentralized visits.",
   "event_date": "2021-12-31",
   "date_precision": "day",
   "evidence_kind": "documented_offer_or_action",
   "sources": [
    "SC1"
   ]
  },
  {
   "id": "science-37-g01",
   "business": "Decentralized clinical-trial technology and delivery",
   "category": "go_to_market",
   "dimension": "Customer concentration",
   "statement": "PPD accounted for 22.9% of 2021 revenue.",
   "event_date": "2021-12-31",
   "date_precision": "day",
   "evidence_kind": "documented_offer_or_action",
   "sources": [
    "SC1"
   ]
  },
  {
   "id": "science-37-p03",
   "business": "Decentralized clinical-trial technology and delivery",
   "category": "product",
   "dimension": "Contract termination",
   "statement": "Many contracts allowed termination without cause with short notice.",
   "event_date": "2022-12-31",
   "date_precision": "day",
   "evidence_kind": "documented_offer_or_action",
   "sources": [
    "SC2"
   ]
  },
  {
   "id": "science-37-g02",
   "business": "Decentralized clinical-trial technology and delivery",
   "category": "go_to_market",
   "dimension": "Cancellations",
   "statement": "Reported cancellation rate increased to 36.9% in 2022.",
   "event_date": "2022-12-31",
   "date_precision": "day",
   "evidence_kind": "documented_offer_or_action",
   "sources": [
    "SC2"
   ]
  },
  {
   "id": "science-37-g03",
   "business": "Decentralized clinical-trial technology and delivery",
   "category": "go_to_market",
   "dimension": "Acquisition",
   "statement": "eMed completed a cash acquisition at $5.75 per share.",
   "event_date": "2024-03-12",
   "date_precision": "day",
   "evidence_kind": "documented_offer_or_action",
   "sources": [
    "SC4"
   ]
  }
 ]
}